MET receptor in oncology: From biomarker to therapeutic target.
Sign Up to like & getrecommendations! Published in 2020 at "Advances in cancer research"
DOI: 10.1016/bs.acr.2020.04.006
Abstract: First discovered in the 1984, the MET receptor tyrosine kinase (RTK) and its ligand hepatocyte growth factor or HGF (also known as scatter factor or SF) are implicated as key players in tumor cell migration,… read more here.
Keywords: receptor oncology; receptor; met receptor; oncology ... See more keywords
QSAR, molecular docking and ADMET properties in silico studies of novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2-Yl derivatives derived from dimedone as potent anti-tumor agents through inhibition of C-Met receptor tyrosine kinase
Sign Up to like & getrecommendations! Published in 2021 at "Heliyon"
DOI: 10.1016/j.heliyon.2021.e07463
Abstract: A quantitative structure-activity relationship (QSAR) study is performed on 48 novel 4,5,6,7-tetrahydrobenzo[D]-thiazol-2 derivatives as anticancer agents capable of inhibiting c-Met receptor tyrosine kinase. The present study is conducted using multiple linear regression, multiple nonlinear regression… read more here.
Keywords: tetrahydrobenzo thiazol; qsar; novel tetrahydrobenzo; receptor ... See more keywords
When the MET receptor kicks in to resist targeted therapies
Sign Up to like & getrecommendations! Published in 2021 at "Oncogene"
DOI: 10.1038/s41388-021-01835-0
Abstract: Although targeted therapies have increased the life expectancy of patients with druggable molecular alterations directly involved in tumor development, the efficacy of these therapies is limited by acquired resistances leading to treatment failure. Most targeted… read more here.
Keywords: kicks resist; receptor kicks; resistance; met receptor ... See more keywords
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Sign Up to like & getrecommendations! Published in 2017 at "Journal Of The National Cancer Institute"
DOI: 10.1093/jnci/djw262
Abstract: Inhibitors of the receptor tyrosine kinase (RTK) MET have been ineffective at treating cancer, possibly because of lack of knowledge that would allow selection of tumors likely to respond to this treatment. In contrast, specific… read more here.
Keywords: biomarker target; exon deleted; new biomarker; deleted met ... See more keywords
Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist
Sign Up to like & getrecommendations! Published in 2022 at "Life Science Alliance"
DOI: 10.26508/lsa.202201424
Abstract: We designed and characterized a potent full MET receptor agonist consisting of two recombinantly linked HGF/SF kringle 1 domains and demonstrated its potential in epithelial tissue regeneration. Hepatocyte growth factor/scatter factor (HGF/SF) and its cognate… read more here.
Keywords: hgf; factor; hepatocyte growth; met receptor ... See more keywords
Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms22179240
Abstract: NK1, a splicing variant of hepatocyte growth factor (HGF), binds to and activates Met receptor by forming an NK1 dimer and 2:2 complex with Met. Although the structural mechanism underlying Met activation by HGF remains… read more here.
Keywords: nk1; dimer; hgf; activation ... See more keywords